单位：[1]Beijing University of Chinese Medicine, Beijing, China[2]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China[3]Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China[4]Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore[5]National Centre for Infectious Diseases, Singapore[6]Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore[7]Yong Loo Lin School of Medicine, National University of Singapore, Singapore[8]Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China[9]Department of Respiratory Medicine, Capital Medical University, Beijing, China
The coronavirus disease 2019 (COVID-19) pandemic is ongoing and many drugs have been studied in clinical trials. From a pathophysiological perspective, anti-viral drugs may be more effective in the early stage while immunomodulators may be more effective in severe patients in later stages of infection. While drugs such as lopinavir-ritonavir, hydroxychloroquine and azithromycin have proved to be ineffective in randomized controlled trials, corticosteroids, neutralizing monoclonal antibodies, remdesivir, tocilizumab and baricitinib have been reported to benefit certain groups of patients with COVID-19. In this review, we will present the key clinical evidence and progress in promising COVID-19 therapeutics, as well as summarize the experience and lessons learned from the development of the current therapeutics.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [82041011, 81970010]
第一作者单位：[1]Beijing University of Chinese Medicine, Beijing, China[2]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China[3]Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China
通讯作者：
通讯机构：[1]Beijing University of Chinese Medicine, Beijing, China[2]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China[3]Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China[8]Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China[9]Department of Respiratory Medicine, Capital Medical University, Beijing, China[*1]China-Japan Friendship Hospital, Beijing, China.
推荐引用方式(GB/T 7714)：
Lianhan Shang,David Chien Lye,Bin Cao.Contemporary narrative review of treatment options for COVID-19[J].RESPIROLOGY.2021,26(8):745-767.doi:10.1111/resp.14106.
APA：
Lianhan Shang,David Chien Lye&Bin Cao.(2021).Contemporary narrative review of treatment options for COVID-19.RESPIROLOGY,26,(8)
MLA：
Lianhan Shang,et al."Contemporary narrative review of treatment options for COVID-19".RESPIROLOGY 26..8(2021):745-767
